SG11202108257TA - Hydroxypyridoxazepines as nrf2 activators - Google Patents
Hydroxypyridoxazepines as nrf2 activatorsInfo
- Publication number
- SG11202108257TA SG11202108257TA SG11202108257TA SG11202108257TA SG11202108257TA SG 11202108257T A SG11202108257T A SG 11202108257TA SG 11202108257T A SG11202108257T A SG 11202108257TA SG 11202108257T A SG11202108257T A SG 11202108257TA SG 11202108257T A SG11202108257T A SG 11202108257TA
- Authority
- SG
- Singapore
- Prior art keywords
- hydroxypyridoxazepines
- nrf2 activators
- nrf2
- activators
- Prior art date
Links
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 title 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806201P | 2019-02-15 | 2019-02-15 | |
| US201962931877P | 2019-11-07 | 2019-11-07 | |
| PCT/IB2020/051100 WO2020165776A1 (en) | 2019-02-15 | 2020-02-11 | Hydroxypyridoxazepines as nrf2 activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108257TA true SG11202108257TA (en) | 2021-08-30 |
Family
ID=69726636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108257TA SG11202108257TA (en) | 2019-02-15 | 2020-02-11 | Hydroxypyridoxazepines as nrf2 activators |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11945826B2 (enExample) |
| EP (1) | EP3924356A1 (enExample) |
| JP (1) | JP7602469B2 (enExample) |
| KR (1) | KR20210126676A (enExample) |
| CN (2) | CN118206566A (enExample) |
| AU (1) | AU2020222080C1 (enExample) |
| BR (1) | BR112021016042A2 (enExample) |
| CA (1) | CA3129955A1 (enExample) |
| CL (1) | CL2021002110A1 (enExample) |
| CO (1) | CO2021010930A2 (enExample) |
| IL (2) | IL285438B2 (enExample) |
| MA (1) | MA54939A (enExample) |
| MX (1) | MX2021009659A (enExample) |
| MY (1) | MY209603A (enExample) |
| PH (1) | PH12021551873A1 (enExample) |
| SG (1) | SG11202108257TA (enExample) |
| TW (2) | TWI843806B (enExample) |
| WO (1) | WO2020165776A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2974026T3 (es) | 2018-08-20 | 2024-06-25 | Janssen Pharmaceutica Nv | Inhibidores de la interacción proteína-proteína entre KEAP1-Nrf2 |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| MY209603A (en) * | 2019-02-15 | 2025-07-24 | Glaxosmithkline Ip Dev Ltd | Hydroxypyridoxazepines as nrf2 activators |
| MX2021014680A (es) * | 2019-05-31 | 2022-04-06 | Ube Corp | Derivado de benzotriazol. |
| PE20241779A1 (es) | 2022-01-07 | 2024-09-03 | Chugai Pharmaceutical Co Ltd | Compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del nrf2 |
| EP4516792A1 (en) * | 2022-04-28 | 2025-03-05 | Kyoto Pharmaceutical Industries, Ltd. | Benzothiophene compound |
| WO2023210741A1 (ja) | 2022-04-28 | 2023-11-02 | 第一三共株式会社 | ベンゾトリアゾール化合物 |
| EP4580612A1 (en) * | 2022-09-02 | 2025-07-09 | Institut National de la Santé et de la Recherche Médicale | Use of nrf2 activators for the treatment of cerebral small vessel disease |
| CN121152792A (zh) * | 2023-06-19 | 2025-12-16 | 中外制药株式会社 | 具有Nrf2活化作用的含氮杂环化合物的晶体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2670099A1 (en) * | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| CN105829305B (zh) * | 2013-12-18 | 2018-11-30 | 葛兰素史密斯克莱知识产权发展有限公司 | Nrf2调节剂 |
| EP3307739B1 (en) * | 2015-06-15 | 2020-10-07 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
| AU2016280235A1 (en) * | 2015-06-15 | 2017-12-14 | Astex Therapeutics Limited | Nrf2 regulators |
| KR20180018684A (ko) | 2015-06-15 | 2018-02-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| CA2995325A1 (en) * | 2015-08-12 | 2017-02-16 | Mochida Pharmaceutical Co., Ltd. | Isothiazole derivative |
| US10364256B2 (en) * | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| CN108779108A (zh) * | 2016-12-06 | 2018-11-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途 |
| EP3551621A1 (en) * | 2016-12-12 | 2019-10-16 | GlaxoSmithKline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
| US11078216B2 (en) * | 2016-12-14 | 2021-08-03 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl amides as NRF2 activators |
| BR112019012300A2 (pt) | 2016-12-15 | 2019-11-12 | Glaxosmithkline Intellectual Property Development Limited | ativadores nrf2 |
| MY209603A (en) * | 2019-02-15 | 2025-07-24 | Glaxosmithkline Ip Dev Ltd | Hydroxypyridoxazepines as nrf2 activators |
-
2020
- 2020-02-11 MY MYPI2021004562A patent/MY209603A/en unknown
- 2020-02-11 CN CN202410206971.5A patent/CN118206566A/zh active Pending
- 2020-02-11 IL IL285438A patent/IL285438B2/en unknown
- 2020-02-11 BR BR112021016042-6A patent/BR112021016042A2/pt unknown
- 2020-02-11 JP JP2021547429A patent/JP7602469B2/ja active Active
- 2020-02-11 WO PCT/IB2020/051100 patent/WO2020165776A1/en not_active Ceased
- 2020-02-11 AU AU2020222080A patent/AU2020222080C1/en active Active
- 2020-02-11 PH PH1/2021/551873A patent/PH12021551873A1/en unknown
- 2020-02-11 US US17/429,088 patent/US11945826B2/en active Active
- 2020-02-11 MX MX2021009659A patent/MX2021009659A/es unknown
- 2020-02-11 KR KR1020217029193A patent/KR20210126676A/ko active Pending
- 2020-02-11 CN CN202080014726.4A patent/CN113474349B/zh active Active
- 2020-02-11 EP EP20708180.3A patent/EP3924356A1/en active Pending
- 2020-02-11 CA CA3129955A patent/CA3129955A1/en active Pending
- 2020-02-11 MA MA054939A patent/MA54939A/fr unknown
- 2020-02-11 IL IL313950A patent/IL313950A/en unknown
- 2020-02-11 SG SG11202108257TA patent/SG11202108257TA/en unknown
- 2020-02-13 TW TW109104455A patent/TWI843806B/zh active
- 2020-02-13 TW TW113112455A patent/TWI880702B/zh active
-
2021
- 2021-08-11 CL CL2021002110A patent/CL2021002110A1/es unknown
- 2021-08-19 CO CONC2021/0010930A patent/CO2021010930A2/es unknown
-
2024
- 2024-02-27 US US18/588,051 patent/US20240352034A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/054,254 patent/US20250313573A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250313573A1 (en) | 2025-10-09 |
| PH12021551873A1 (en) | 2022-05-23 |
| WO2020165776A1 (en) | 2020-08-20 |
| CL2021002110A1 (es) | 2022-02-11 |
| TWI880702B (zh) | 2025-04-11 |
| EP3924356A1 (en) | 2021-12-22 |
| MY209603A (en) | 2025-07-24 |
| JP7602469B2 (ja) | 2024-12-18 |
| IL313950A (en) | 2024-08-01 |
| US11945826B2 (en) | 2024-04-02 |
| CN118206566A (zh) | 2024-06-18 |
| TWI843806B (zh) | 2024-06-01 |
| CO2021010930A2 (es) | 2021-09-09 |
| TW202440593A (zh) | 2024-10-16 |
| US20220204526A1 (en) | 2022-06-30 |
| JP2022520442A (ja) | 2022-03-30 |
| CA3129955A1 (en) | 2020-08-20 |
| IL285438B2 (en) | 2024-12-01 |
| MX2021009659A (es) | 2021-09-08 |
| CN113474349B (zh) | 2024-03-01 |
| MA54939A (fr) | 2021-12-22 |
| US20240352034A1 (en) | 2024-10-24 |
| TW202045514A (zh) | 2020-12-16 |
| KR20210126676A (ko) | 2021-10-20 |
| AU2020222080B2 (en) | 2022-05-19 |
| AU2020222080A1 (en) | 2021-09-02 |
| BR112021016042A2 (pt) | 2021-10-05 |
| CN113474349A (zh) | 2021-10-01 |
| IL285438A (en) | 2021-09-30 |
| IL285438B1 (en) | 2024-08-01 |
| AU2020222080C1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285438A (en) | Hydroxypyridoxazepines as activators of nrf2 | |
| GB201903287D0 (en) | Composition | |
| GB201912061D0 (en) | Composition | |
| GB201913593D0 (en) | Composition | |
| IL267692B (en) | activator of nrf2 | |
| GB201917899D0 (en) | New composition | |
| GB201916374D0 (en) | Composition | |
| GB201910873D0 (en) | Novel uses | |
| GB201911454D0 (en) | Composition | |
| GB201907225D0 (en) | Composition | |
| HK40106672A (zh) | 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯 | |
| GB202002865D0 (en) | Composition | |
| GB201918997D0 (en) | Composition | |
| GB201917191D0 (en) | Composition | |
| GB201914325D0 (en) | Novel meethod | |
| GB201916352D0 (en) | Composition | |
| GB201911461D0 (en) | Novel composition | |
| GB2581344B (en) | Novel composition | |
| GB201903406D0 (en) | Composition | |
| GB201902054D0 (en) | Composition | |
| HK40059420A (en) | Hydroxypyridoxazepines as nrf2 activators | |
| GB201917385D0 (en) | Adhesive composition | |
| GB202004080D0 (en) | Composition | |
| GB201912777D0 (en) | Structural materials | |
| GB201919296D0 (en) | Composition |